Artivion (AORT) Competitors $40.91 -0.19 (-0.46%) Closing price 09/24/2025 03:59 PM EasternExtended Trading$40.04 -0.87 (-2.13%) As of 09/24/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AORT vs. IRTC, BLCO, GKOS, TMDX, NVST, LIVN, SLNO, WRBY, INSP, and LQDAShould you be buying Artivion stock or one of its competitors? The main competitors of Artivion include iRhythm Technologies (IRTC), Bausch + Lomb (BLCO), Glaukos (GKOS), TransMedics Group (TMDX), Envista (NVST), LivaNova (LIVN), Soleno Therapeutics (SLNO), Warby Parker (WRBY), Inspire Medical Systems (INSP), and Liquidia Technologies (LQDA). These companies are all part of the "medical equipment" industry. Artivion vs. Its Competitors iRhythm Technologies Bausch + Lomb Glaukos TransMedics Group Envista LivaNova Soleno Therapeutics Warby Parker Inspire Medical Systems Liquidia Technologies Artivion (NYSE:AORT) and iRhythm Technologies (NASDAQ:IRTC) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership. Does the media prefer AORT or IRTC? In the previous week, iRhythm Technologies had 13 more articles in the media than Artivion. MarketBeat recorded 14 mentions for iRhythm Technologies and 1 mentions for Artivion. Artivion's average media sentiment score of 1.36 beat iRhythm Technologies' score of 0.95 indicating that Artivion is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Artivion 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive iRhythm Technologies 6 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer AORT or IRTC? Artivion currently has a consensus price target of $40.63, suggesting a potential downside of 0.68%. iRhythm Technologies has a consensus price target of $165.58, suggesting a potential downside of 4.80%. Given Artivion's stronger consensus rating and higher probable upside, analysts clearly believe Artivion is more favorable than iRhythm Technologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Artivion 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00iRhythm Technologies 0 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.92 Which has better valuation & earnings, AORT or IRTC? Artivion has higher earnings, but lower revenue than iRhythm Technologies. Artivion is trading at a lower price-to-earnings ratio than iRhythm Technologies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArtivion$388.54M4.97-$13.36M-$0.42-97.40iRhythm Technologies$657.23M8.50-$113.29M-$2.93-59.36 Which has more volatility and risk, AORT or IRTC? Artivion has a beta of 1.7, suggesting that its share price is 70% more volatile than the S&P 500. Comparatively, iRhythm Technologies has a beta of 1.1, suggesting that its share price is 10% more volatile than the S&P 500. Do insiders and institutionals have more ownership in AORT or IRTC? 86.4% of Artivion shares are held by institutional investors. 7.6% of Artivion shares are held by insiders. Comparatively, 1.1% of iRhythm Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Is AORT or IRTC more profitable? Artivion has a net margin of -4.43% compared to iRhythm Technologies' net margin of -14.06%. Artivion's return on equity of 5.70% beat iRhythm Technologies' return on equity.Company Net Margins Return on Equity Return on Assets Artivion-4.43% 5.70% 2.29% iRhythm Technologies -14.06%-90.03%-8.52% SummaryArtivion beats iRhythm Technologies on 11 of the 16 factors compared between the two stocks. Get Artivion News Delivered to You Automatically Sign up to receive the latest news and ratings for AORT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AORT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AORT vs. The Competition Export to ExcelMetricArtivionMED INSTRUMENTS IndustryMedical SectorNYSE ExchangeMarket Cap$1.94B$6.74B$5.77B$21.69BDividend YieldN/A1.20%5.68%3.52%P/E Ratio-97.4025.4476.2829.43Price / Sales4.97197.32552.2884.67Price / Cash49.2621.7937.5624.47Price / Book6.215.0613.184.56Net Income-$13.36M$178.07M$3.29B$1.00B7 Day Performance-1.16%-1.49%0.84%-0.51%1 Month Performance-6.02%6.23%5.03%2.89%1 Year Performance61.70%22.47%71.27%14.77% Artivion Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AORTArtivion2.6071 of 5 stars$40.91-0.5%$40.63-0.7%+60.4%$1.94B$388.54M-97.401,600Positive NewsIRTCiRhythm Technologies1.1351 of 5 stars$176.16-2.0%$163.82-7.0%+147.4%$5.78B$657.23M-60.122,000Analyst ForecastBLCOBausch + Lomb2.2093 of 5 stars$15.23+0.2%$15.56+2.2%-21.8%$5.38B$4.79B-19.5213,500GKOSGlaukos4.6206 of 5 stars$80.72-2.5%$124.83+54.6%-35.2%$4.75B$383.48M-48.92780Analyst ForecastTMDXTransMedics Group2.4791 of 5 stars$114.29-0.2%$122.11+6.8%-24.7%$3.91B$441.54M59.22210NVSTEnvista3.8213 of 5 stars$21.12+0.5%$20.92-0.9%+9.3%$3.49B$2.51B65.9912,300Positive NewsLIVNLivaNova3.0102 of 5 stars$55.43-1.4%$59.71+7.7%+3.4%$3.07B$1.25B-14.252,900Positive NewsSLNOSoleno Therapeutics4.4457 of 5 stars$51.17-4.6%$115.09+124.9%+37.6%$2.85BN/A-12.3630Trending NewsGap UpWRBYWarby Parker1.6316 of 5 stars$26.37-1.4%$24.06-8.8%+85.2%$2.81B$771.32M-376.723,780INSPInspire Medical Systems4.8276 of 5 stars$80.90+1.1%$164.50+103.3%-62.5%$2.37B$802.80M46.761,246Analyst DowngradeLQDALiquidia Technologies3.9409 of 5 stars$26.77+3.0%$32.11+20.0%+116.8%$2.24B$14M-15.7550 Related Companies and Tools Related Companies iRhythm Technologies Competitors Bausch + Lomb Competitors Glaukos Competitors TransMedics Group Competitors Envista Competitors LivaNova Competitors Soleno Therapeutics Competitors Warby Parker Competitors Inspire Medical Systems Competitors Liquidia Technologies Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:AORT) was last updated on 9/25/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Artivion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Artivion With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
